Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
June 05, 2024
In 2015 the nations of the world agreed at the United Nations on 17 Sustainable Development Goals (SDGs) to be reached by 2030. The SDGs are the closest the world has come to a definable and measurable global social contract.
The SDGs do not constitute a legally binding contract; there are no pen...
Blog Post
May 10, 2024
Here is a Mother’s Day shout-out to all the mothers working at international financial institutions (IFIs) around the world, and especially to mothers at the two banks I know best: the World Bank and the Inter-American Development Bank, where I worked for a total of almost two decades with at least ...
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
October 24, 2023
I was thrilled when I read last week that Claudia Goldin had won the Nobel Prize in Economics. I have never met her but you could say I discovered her 20 years ago when her 2003 study with Lawrence Katz entitled “The Power of the Pill: Oral Contraceptives and Women’s Career and Marriage Decisions” w...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...